HARS1

Chr 5ADAR

histidyl-tRNA synthetase 1

Also known as: CMT2W, HARS, HRS, USH3B

Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. The protein encoded by this gene is a cytoplasmic enzyme which belongs to the class II family of aminoacyl-tRNA synthetases. The enzyme is responsible for the synthesis of histidyl-transfer RNA, which is essential for the incorporation of histidine into proteins. The gene is located in a head-to-head orientation with HARSL on chromosome five, where the homologous genes share a bidirectional promoter. The gene product is a frequent target of autoantibodies in the human autoimmune disease polymyositis/dermatomyositis. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

GeneReviewsOMIMResearchGenerating clinical summary…
DNmechanismAD/ARLOEUF 0.762 OMIM phenotypes
Clinical SummaryHARS1
🧬
Gene-Disease Validity (ClinGen)
Usher syndrome type 3 · ARRefuted

Refuted — evidence has disproved this relationship

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
6 unique Pathogenic / Likely Pathogenic· 347 VUS of 601 total submissions
📖
GeneReview available — HARS1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.76LOEUF
pLI 0.000
Z-score 2.54
OE 0.49 (0.320.76)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
1.26Z-score
OE missense 0.80 (0.710.89)
239 obs / 300.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.49 (0.320.76)
00.351.4
Missense OE?0.80 (0.710.89)
00.61.4
Synonymous OE?0.85
01.21.6
LoF obs/exp: 14 / 28.7Missense obs/exp: 239 / 300.5Syn Z: 1.23
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedHARS1-related Usher syndromeOTHERAR

This gene — mechanism propensity

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.7133th %ile
GOF
0.5071th %ile
LOF
0.3552th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Literature Evidence

DNEvidence for a dominant-negative mechanism in HARS1-mediated peripheral neuropathy.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 32940403

ClinVar Variant Classifications

601 submitted variants in ClinVar

Classification Summary

Pathogenic3
Likely Pathogenic3
VUS347
Likely Benign199
Benign17
Conflicting21
3
Pathogenic
3
Likely Pathogenic
347
VUS
199
Likely Benign
17
Benign
21
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
2
1
0
3
Likely Pathogenic
1
1
1
0
3
VUS
35
274
33
5
347
Likely Benign
0
4
102
93
199
Benign
0
0
16
1
17
Conflicting
21
Total3628115399590

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

6 pathogenic / likely-pathogenic (of 10) ClinVar copy-number / structural variants overlap HARS1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

HARS1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →